NO20065762L - Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer. - Google Patents
Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.Info
- Publication number
- NO20065762L NO20065762L NO20065762A NO20065762A NO20065762L NO 20065762 L NO20065762 L NO 20065762L NO 20065762 A NO20065762 A NO 20065762A NO 20065762 A NO20065762 A NO 20065762A NO 20065762 L NO20065762 L NO 20065762L
- Authority
- NO
- Norway
- Prior art keywords
- pyrrolypyrimidine
- prodrugs
- protein kinase
- kinase inhibitors
- erk protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57128304P | 2004-05-14 | 2004-05-14 | |
PCT/US2005/016801 WO2005113546A1 (en) | 2004-05-14 | 2005-05-13 | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065762L true NO20065762L (no) | 2007-02-12 |
Family
ID=35159977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065762A NO20065762L (no) | 2004-05-14 | 2006-12-13 | Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US7358258B2 (zh) |
EP (1) | EP1753744B1 (zh) |
JP (1) | JP4993604B2 (zh) |
KR (1) | KR20070012555A (zh) |
CN (1) | CN1976925A (zh) |
AT (1) | ATE435858T1 (zh) |
AU (1) | AU2005245877B2 (zh) |
BR (1) | BRPI0511124A (zh) |
CA (1) | CA2566444A1 (zh) |
DE (1) | DE602005015319D1 (zh) |
IL (1) | IL179206A0 (zh) |
MX (1) | MXPA06013208A (zh) |
NO (1) | NO20065762L (zh) |
NZ (1) | NZ551583A (zh) |
RU (1) | RU2006144448A (zh) |
UA (1) | UA84929C2 (zh) |
WO (1) | WO2005113546A1 (zh) |
ZA (1) | ZA200610163B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
ATE485268T1 (de) | 2006-02-16 | 2010-11-15 | Schering Corp | Pyrrolidin-derivate als erk-hemmer |
US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
JP2013147428A (ja) * | 2010-04-27 | 2013-08-01 | Dainippon Sumitomo Pharma Co Ltd | 新規2−ヘテロアリール単環ピリミジン誘導体 |
CN103617111A (zh) * | 2011-04-01 | 2014-03-05 | 北京奇虎科技有限公司 | 一种计算机功耗计算方法及装置 |
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
EP3424920B1 (en) | 2013-10-17 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
EP3061754A4 (en) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10479791B2 (en) | 2015-06-03 | 2019-11-19 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as ERK inhibitors |
BR112017026159A2 (pt) * | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
AU2017335648B2 (en) | 2016-09-27 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
DE60120219T2 (de) * | 2000-12-21 | 2007-04-12 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinase-inhibitoren |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
-
2005
- 2005-05-13 MX MXPA06013208A patent/MXPA06013208A/es not_active Application Discontinuation
- 2005-05-13 CA CA002566444A patent/CA2566444A1/en not_active Abandoned
- 2005-05-13 AU AU2005245877A patent/AU2005245877B2/en not_active Expired - Fee Related
- 2005-05-13 WO PCT/US2005/016801 patent/WO2005113546A1/en active Application Filing
- 2005-05-13 AT AT05756023T patent/ATE435858T1/de not_active IP Right Cessation
- 2005-05-13 CN CNA2005800214194A patent/CN1976925A/zh active Pending
- 2005-05-13 NZ NZ551583A patent/NZ551583A/en unknown
- 2005-05-13 BR BRPI0511124-2A patent/BRPI0511124A/pt not_active IP Right Cessation
- 2005-05-13 EP EP05756023A patent/EP1753744B1/en active Active
- 2005-05-13 DE DE602005015319T patent/DE602005015319D1/de active Active
- 2005-05-13 KR KR1020067026319A patent/KR20070012555A/ko not_active Application Discontinuation
- 2005-05-13 UA UAA200613207A patent/UA84929C2/ru unknown
- 2005-05-13 ZA ZA200610163A patent/ZA200610163B/en unknown
- 2005-05-13 RU RU2006144448/04A patent/RU2006144448A/ru not_active Application Discontinuation
- 2005-05-13 JP JP2007513409A patent/JP4993604B2/ja not_active Expired - Fee Related
- 2005-05-13 US US11/129,114 patent/US7358258B2/en not_active Expired - Fee Related
-
2006
- 2006-11-13 IL IL179206A patent/IL179206A0/en unknown
- 2006-12-13 NO NO20065762A patent/NO20065762L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2006144448A (ru) | 2008-06-20 |
CA2566444A1 (en) | 2005-12-01 |
DE602005015319D1 (de) | 2009-08-20 |
EP1753744A1 (en) | 2007-02-21 |
NZ551583A (en) | 2009-05-31 |
WO2005113546A1 (en) | 2005-12-01 |
MXPA06013208A (es) | 2007-01-16 |
EP1753744B1 (en) | 2009-07-08 |
US7358258B2 (en) | 2008-04-15 |
CN1976925A (zh) | 2007-06-06 |
BRPI0511124A (pt) | 2007-11-27 |
KR20070012555A (ko) | 2007-01-25 |
JP2007537293A (ja) | 2007-12-20 |
AU2005245877A1 (en) | 2005-12-01 |
AU2005245877B2 (en) | 2010-06-03 |
IL179206A0 (en) | 2007-03-08 |
ATE435858T1 (de) | 2009-07-15 |
US20060058318A1 (en) | 2006-03-16 |
UA84929C2 (en) | 2008-12-10 |
ZA200610163B (en) | 2008-02-27 |
JP4993604B2 (ja) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
NO20065762L (no) | Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer. | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
SG151327A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
TW200604168A (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
NO20080967L (no) | Benzimidazoler nyttige som inhibitorer av proteinkinaser | |
MX2009005231A (es) | Composiciones utiles como inhibidores de proteina cinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |